CN116261450A - 癌症肽疫苗及其制备方法 - Google Patents
癌症肽疫苗及其制备方法 Download PDFInfo
- Publication number
- CN116261450A CN116261450A CN202180066525.3A CN202180066525A CN116261450A CN 116261450 A CN116261450 A CN 116261450A CN 202180066525 A CN202180066525 A CN 202180066525A CN 116261450 A CN116261450 A CN 116261450A
- Authority
- CN
- China
- Prior art keywords
- peptide
- seq
- cancer
- leu
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/34—Antigenic peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020-128412 | 2020-07-29 | ||
| JP2020128412 | 2020-07-29 | ||
| PCT/JP2021/027832 WO2022025093A1 (ja) | 2020-07-29 | 2021-07-28 | がんペプチドワクチンおよびその製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116261450A true CN116261450A (zh) | 2023-06-13 |
Family
ID=80035678
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180066525.3A Pending CN116261450A (zh) | 2020-07-29 | 2021-07-28 | 癌症肽疫苗及其制备方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230321241A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JPWO2022025093A1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN116261450A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022025093A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024149926A (ja) * | 2021-08-06 | 2024-10-23 | ブライトパス・バイオ株式会社 | がんペプチドワクチンカクテル製剤、及びその製造方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015120231A2 (en) * | 2014-02-06 | 2015-08-13 | Xeris Phrmaceuticals, Inc. | Stable peptide formulations and methods for preparation |
-
2021
- 2021-07-28 JP JP2022539513A patent/JPWO2022025093A1/ja active Pending
- 2021-07-28 WO PCT/JP2021/027832 patent/WO2022025093A1/ja not_active Ceased
- 2021-07-28 CN CN202180066525.3A patent/CN116261450A/zh active Pending
- 2021-07-28 US US18/018,380 patent/US20230321241A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20230321241A1 (en) | 2023-10-12 |
| JPWO2022025093A1 (cg-RX-API-DMAC7.html) | 2022-02-03 |
| WO2022025093A1 (ja) | 2022-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20220044481A (ko) | 암 면역요법을 위한 조성물 및 방법 | |
| JP6224268B2 (ja) | 子宮内膜癌の治療において使用するためのデュオカルマイシンadc | |
| EP3773714A1 (en) | Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody | |
| ES2825080T3 (es) | Anticuerpos humanizados contra CEACAM1 | |
| EP3876978A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| US9757439B2 (en) | Peptide vaccine comprising mutant RAS peptide and chemotherapeutic agent | |
| KR20170003575A (ko) | 비-소세포 폐암을 치료하기 위한 항-b7-h1 및 항-ctla-4 항체 | |
| EP3545969A1 (en) | Dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates | |
| KR20180038550A (ko) | 다양한 암의 면역요법 치료에서의 사용을 위한 신규 펩티드, 펩티드의 조합 및 골격 | |
| KR20180085725A (ko) | 다양한 암에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합 | |
| JP2023036999A (ja) | 免疫応答を調節するためのオキサビシクロヘプタン | |
| KR102043725B1 (ko) | 뇌 전이 치료를 위한 치료용 다중 펩타이드 t 특이적 면역 요법 | |
| KR20200112904A (ko) | 암을 치료하는 조성물 및 방법 | |
| KR102921677B1 (ko) | 수용성 보조제 | |
| EP2591799A1 (en) | Cancer peptide vaccine | |
| US20230321241A1 (en) | Cancer peptide vaccine and method of preparing the same | |
| KR20090112590A (ko) | 백신을 위한 인간 조직 적합성 항원(hla) 종류 i 또는 ii 분자에 결합하는 종양 관련 펩티드의 새로운 제형 | |
| KR20250092133A (ko) | 면역억제성 종양미세환경을 조절하는 항체-펩타이드 융합체 및 이의 항암용도 | |
| JP2024149926A (ja) | がんペプチドワクチンカクテル製剤、及びその製造方法 | |
| US20250296966A1 (en) | Combination of an antibody specific for a tumor antigen and a cd47 inhibitor | |
| EP4338742A1 (en) | Application of hydroxyprogesterone caproate in enhancing tumor treatment effect | |
| EP4491194A1 (en) | Triple combination drug dosing therapy for head and neck cancer treatment | |
| CN111727060B (zh) | 治疗癌症的激动剂抗PD-1抗体与GnRH激动剂或GnRH拮抗剂的组合 | |
| CN116685352A (zh) | 用gm-csf拮抗剂治疗癌症 | |
| JP2021504378A (ja) | 改良されたがんの処置 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |